Vaccines, Blood & Biologics

June 9, 2009 Approval Letter - Gardasil

Our STN:  BL 125126/1256

Merck & Co
Attention:  Patrick Brill-Edwards, M.D.
P.O. Box 1000
UG2D-68
North Wales, PA 19454-1099

Dear Dr. Brill-Edwards:

We have approved your request to supplement your biologics license application for Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, GARDASIL® for the following changes to the package insert:

  • The addition of “chills” to the Postmarketing Adverse Reactions section,
  • The addition of a new System Organ Class “Respiratory, thoracic and mediastinal disorders” and relocation of the adverse experience “pulmonary embolus” into this class,
  • The addition of “Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL,” to the Warnings and Precautions section.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h.  Please provide content of labeling in Structured Product Labeling format.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

--signature--

Wellington Sun, M.D.
Director
Division of Vaccines and Related Products Applications
Office of Vaccine Research and Review
Center for Biologics Evaluation and Research

Attachment: Approved Final Draft Labeling

 

Resources for You

Page Last Updated: 07/17/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.